MARKET

CORT

CORT

Corcept
NASDAQ

Real-time Quotes | Nasdaq Last Sale

11.70
+0.83
+7.64%
Closed 16:07 03/30 EDT
OPEN
11.03
PREV CLOSE
10.87
HIGH
11.74
LOW
11.00
VOLUME
1.22M
TURNOVER
--
52 WEEK HIGH
17.48
52 WEEK LOW
9.55
MARKET CAP
1.34B
P/E (TTM)
15.22
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CORT and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CORT stock price target is 17.20 with a high estimate of 26.00 and a low estimate of 11.00.

EPS

CORT News

More
  • Update: Corcept Therapeutics (NASDAQ:CORT) Stock Gained 88% In The Last Five Years
  • Simply Wall St. · 4d ago
  • Healthcare And Biotechnology Dashboard - Update
  • Seeking Alpha - Article · 6d ago
  • Corcept (CORT) Down 24.9% Since Last Earnings Report: Can It Rebound?
  • Zacks · 03/21 16:30
  • Corcept Therapeutics Appoints Gregg Alton to Board of Directors
  • GlobeNewswire · 03/12 13:30

Industry

Pharmaceuticals
+4.97%
Pharmaceuticals & Medical Research
+4.75%

Hot Stocks

Symbol
Price
%Change

About CORT

Corcept Therapeutics Incorporated is a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders. The Company is developing mifepristone, a compound that modulates the effects of cortisol by acting as a competitive antagonist at the glucocorticoid receptor (GR). As of December 31, 2016, it had discovered three structurally distinct series of selective cortisol modulators, all of which share mifepristone's affinity for GR but, unlike mifepristone, do not bind to the progesterone receptor. It is conducting two clinical trials of its selective cortisol modulator, CORT125134. One trial is investigating CORT125134 as a treatment for patients with Cushing syndrome. The second trial is investigating the combination of CORT125134 and nab-paclitaxel (Celgene Corporation's Abraxane) to treat patients with solid-tumor cancers.
More

Webull offers kinds of Corcept Therapeutics Incorporated stock information, including NASDAQ:CORT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CORT stock news, and many more online research tools to help you make informed decisions.